148 related articles for article (PubMed ID: 15962840)
21. Anthracycline-induced cardiotoxicity in children with malignancies.
Godoy LY; Fukushige J; Igarashi H; Matsuzaki A; Ueda K
Acta Paediatr Jpn; 1997 Apr; 39(2):188-93. PubMed ID: 9141252
[TBL] [Abstract][Full Text] [Related]
22. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
Lenihan DJ; Stevens PL; Massey M; Plana JC; Araujo DM; Fanale MA; Fayad LE; Fisch MJ; Yeh ET
J Card Fail; 2016 Jun; 22(6):433-8. PubMed ID: 27079675
[TBL] [Abstract][Full Text] [Related]
23. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
[TBL] [Abstract][Full Text] [Related]
24. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
25. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
Messinger Y; Uckun FM
Leuk Lymphoma; 1999 Aug; 34(5-6):415-32. PubMed ID: 10492065
[TBL] [Abstract][Full Text] [Related]
26. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
27. Speckle-Tracking Echocardiography to Detect Cardiac Toxicity in Children Who Received Anthracyclines During Pregnancy.
Avilès A; Nambo MJ; Huerta-Guzmàn J; Neri N; Cleto S
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):1-4. PubMed ID: 26549215
[TBL] [Abstract][Full Text] [Related]
28. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
Leblanc T; Deméocq F; Leverger G; Baruchel A; Lemerle S; Vannier JP; Nelken B; Guillot T; Schaison G
Med Pediatr Oncol; 1994; 22(2):119-24. PubMed ID: 8259097
[TBL] [Abstract][Full Text] [Related]
29. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
30. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
31. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
[TBL] [Abstract][Full Text] [Related]
32. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
[TBL] [Abstract][Full Text] [Related]
33. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity.
Horacek JM; Tichy M; Pudil R; Jebavy L
Ann Oncol; 2008 Sep; 19(9):1656-7. PubMed ID: 18622008
[No Abstract] [Full Text] [Related]
34. Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma.
Krawczuk-Rybak M; Dakowicz L; Hryniewicz A; Maksymiuk A; Zelazowska-Rutkowska B; Wysocka J
J Paediatr Child Health; 2011 Jul; 47(7):455-9. PubMed ID: 21332587
[TBL] [Abstract][Full Text] [Related]
35. Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy.
Song FY; Shi J; Guo Y; Zhang CJ; Xu YC; Zhang QL; Shu XH; Cheng LL
Int J Cardiovasc Imaging; 2017 Jun; 33(6):857-868. PubMed ID: 28255826
[TBL] [Abstract][Full Text] [Related]
36. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
37. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study.
Mathew P; Suarez W; Kip K; Bayar E; Jasty R; Matloub Y; Raisch D
Cancer Invest; 2001; 19(4):352-9. PubMed ID: 11405175
[TBL] [Abstract][Full Text] [Related]
38. Potential Biomarker of Acute Anthracycline-induced Cardiotoxicity Among Children With Acute Lymphoblastic Leukemia: Cardiac Adriamycin-responsive Protein.
Li Y; Tian C; Huang S; Wang Y; Qiu J; Ning F; Guo J; Chen Q; Chen R; Ma G
J Cardiovasc Pharmacol; 2023 Dec; 82(6):489-495. PubMed ID: 37678278
[TBL] [Abstract][Full Text] [Related]
39. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
[TBL] [Abstract][Full Text] [Related]
40. Establishing a gradient of risk in patients with acute coronary syndromes using troponin I measurements.
al-Harbi K; Suresh CG; Zubaid M; Akanji AO
Med Princ Pract; 2002; 11(1):18-22. PubMed ID: 12116689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
